U.S. Residential REITs Stock News

NYSE:CURB
NYSE:CURBRetail REITs

How Weaker Profitability And Lower 2026 EPS Guidance At Curbline Properties (CURB) Has Changed Its Investment Story

Curbline Properties Corp. recently reported past second-quarter 2026 results showing sales of US$63.08 million and revenue of US$63.3 million, up from US$41.1 million and US$41.4 million a year earlier, while net income fell to US$6.91 million from US$10.39 million and earnings per share from continuing operations declined to US$0.06 from US$0.10. Alongside these results, management lowered full‑year 2026 earnings guidance to net income per diluted share of US$0.27–US$0.32, highlighting...
NYSE:ITT
NYSE:ITTMachinery

ITT (ITT) Is Up 6.8% After Raising 2026 EPS Guidance Despite Weaker Q2 Earnings

ITT Inc. reported past second-quarter 2026 results with sales rising to US$1,473.1 million from US$972.4 million a year earlier, while net income and diluted EPS from continuing operations declined year-on-year, and the company affirmed a quarterly dividend of US$0.386 per share. Despite lower reported earnings, ITT raised its full-year 2026 EPS and operating margin guidance, linking weaker current profitability to acquisition-related impacts and planned integration benefits that management...
NasdaqCM:OBX
NasdaqCM:OBXBiotechs

Obsidian Therapeutics (OBX) Reached A Trial Milestone, Does The Valuation Already Look Full?

Why Obsidian Therapeutics Stock Is Back in Focus After New Trial Milestone Obsidian Therapeutics (OBX) is drawing fresh attention after enrolling the first patient in a registration enabling cohort of its Phase 1/2 Agni-01 trial for amsoki-cel in advanced melanoma. See our latest analysis for Obsidian Therapeutics. The trial milestone comes after a sharp rebound in Obsidian Therapeutics’ share price, with a 1 day share price return of 27.27% and a year to date share price return of 435.22%...
NYSEAM:UMAC
NYSEAM:UMACElectronic

Can Unusual Machines (UMAC) Justify Its Valuation On Q2 Growth And New Targets?

Unusual Machines (UMAC) drew fresh attention after reporting Q2 2026 results that showed higher enterprise driven sales, a continued net loss, and positive earnings for the first half alongside new internal revenue targets. See our latest analysis for Unusual Machines. Against that backdrop, Unusual Machines’ recent Q2 update and upcoming conference appearance have coincided with strong momentum, including a 30 day share price return of 44.29% and a 1 year total shareholder return of...
NasdaqGS:CLBK
NasdaqGS:CLBKBanks

How Investors May Respond To Columbia Financial (CLBK) Earnings, Dividend, and ESOP-Linked Shelf Registration

Columbia Financial, Inc. recently reported second-quarter 2026 results showing higher net interest income of US$62.92 million and net income of US$14.49 million versus the prior year, while affirming a US$0.05 quarterly dividend and posting lower net charge-offs of US$2.0 million. Together with a new shelf registration for common stock tied to its ESOP and board expansion following the Northfield Bancorp acquisition, these updates highlight how Columbia Financial is balancing growth...
NYSE:CRGY
NYSE:CRGYOil and Gas

Crescent Energy (CRGY) Raises Production Guidance, Is The Stock Still Below Fair Value?

Crescent Energy (CRGY) has drawn fresh attention after raising its full year 2026 production guidance to a range of 327,000 to 335,000 barrels of oil equivalent per day, following a strong second quarter earnings report. See our latest analysis for Crescent Energy. The guidance upgrade and strong second quarter numbers have coincided with a clear pickup in momentum for Crescent Energy, with a 1 month share price return of 28.93% and a 43.48% year to date share price return. The 1 year total...
NasdaqGM:BCAX
NasdaqGM:BCAXBiotechs

Bicara Therapeutics (BCAX) Board Additions Put Its Undervalued Narrative Back In Focus

Why Bicara Therapeutics stock is back in focus Bicara Therapeutics (BCAX) has drawn fresh attention after appointing industry veterans Jeremy Bender and Christy Oliger to its Board of Directors, underscoring its boardroom depth ahead of its upcoming Q2 2026 earnings release. See our latest analysis for Bicara Therapeutics. For investors tracking the bigger picture, Bicara Therapeutics’ share price is US$27.73, with a 7-day share price return of 7.73% and a year to date share price return of...
NasdaqGS:WDC
NasdaqGS:WDCTech

AI Infrastructure Stocks Backed by Data Center Demand and Earnings Growth

Global bond markets are reacting to softer recent US payroll data, which has eased expectations for rapid interest rate moves. That puts more focus on where real cash flows are being generated right now. AI infrastructure stocks sit at the heart of this story. They help power AI data centers that still need energy, cooling, and hardware. This article highlights three stocks from the AI Infrastructure Stocks screener that stand out. The three stocks below are just a starting sample from this...
NasdaqGS:HLNE
NasdaqGS:HLNECapital Markets

Hamilton Lane (HLNE) Is Up 5.7% After Dividend Hike And Strong Q1 Earnings - Has The Bull Case Changed?

Hamilton Lane has already declared a quarterly dividend of US$0.60 per Class A share, payable on October 6, 2026 to shareholders of record on September 21, 2026, lifting its full-year dividend target to US$2.40, an 11% increase from the prior fiscal year. Alongside this higher dividend, Hamilton Lane’s first-quarter results showed revenue rising to US$275.33 million and net income to US$80.46 million, highlighting stronger earnings power that may influence how investors view the balance...
NYSE:VNT
NYSE:VNTElectronic

The Bull Case For Vontier (VNT) Could Change Following A Massive Buyback And Updated 2026 Guidance

In the past week, Vontier Corporation reported second-quarter 2026 results showing sales of US$756.7 million and net income of US$27.4 million, alongside updated full-year and third-quarter sales guidance, and confirmed it has completed a US$1.17 billion share repurchase program launched in 2021. While quarterly earnings softened year on year, the completion of a buyback covering almost one-quarter of shares points to a significant shift in Vontier’s capital allocation and balance between...
NYSE:TPB
NYSE:TPBTobacco

Turning Point Brands (TPB) Stock Climbed, What Is Driving Attention Now?

Why Turning Point Brands stock is back in focus Turning Point Brands (TPB) is drawing fresh attention after its Modern Oral segment drove a sharp year over year jump in second quarter sales and management raised full year Modern Oral guidance. See our latest analysis for Turning Point Brands. The recent Modern Oral guidance upgrade comes as Turning Point Brands trades at US$89.38, with a 1-day share price return of 2.90% and a 7-day share price return of 11.14%. This is despite the share...
NasdaqGS:LBRD.K
NasdaqGS:LBRD.KMedia

Liberty Broadband (LBRD.K) Swung To A Q2 Loss, Is The Stock Too Pricey?

What the latest Liberty Broadband earnings mean for shareholders Liberty Broadband (LBRD.K) has moved back into focus after its second quarter 2026 earnings showed a shift from a prior profit to a substantial net loss, a clear change in recent financial performance. The company reported a second quarter net loss of US$2,125 million, compared with net income of US$383 million a year earlier. Basic and diluted loss per share from continuing operations were US$14.86, replacing the prior year's...
NasdaqGS:DXCM
NasdaqGS:DXCMMedical Equipment

Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM)

In July 2026, DexCom, Inc. reported second-quarter results showing higher sales of US$1,308.4 million and increased net income of US$249.1 million compared with the prior year, and also raised its full-year 2026 revenue guidance to a range of US$5.18 billion to US$5.25 billion. The combination of stronger quarterly earnings and higher full-year revenue guidance suggests management’s confidence in DexCom’s current operating momentum and demand for its continuous glucose monitoring...
NasdaqGS:DRVN
NasdaqGS:DRVNConsumer Services

Driven Brands (DRVN) Faces Activist Pressure Over Rejected Buyout Bid Is Governance Now Center Stage?

In early August 2026, ADW Capital Management publicly challenged Driven Brands Holdings Inc.’s Board and major shareholder Roark Capital Group, criticizing the unanimous rejection of its all-cash US$18.00 per share bid and demanding an immediate strategic review, including potential whole-company or segment sales, while highlighting concerns over governance, delayed filings, and shareholder treatment. ADW’s threat that minority investors may pursue legal remedies, coupled with its push for...
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

Does RUM’s AI Pivot And Northern Data Deal Redraw The Bull Case For RUM Group (RUM)?

RUM Group Inc. has reported past second-quarter 2026 results showing sales rising to US$40.37 million from US$25.08 million a year earlier, while net loss widened to US$79.14 million and loss per share increased to US$0.28. Beyond the headline loss, the company delivered revenue ahead of expectations and completed the Northern Data acquisition, rebranding as RUM Group to pair its Rumble video platform with the new Quake AI infrastructure business. Next, we’ll examine how the Northern Data...
NYSE:KNF
NYSE:KNFBasic Materials

Is Knife River (KNF) Undervalued After Raising Full Year Revenue Guidance?

Knife River (KNF) drew investor attention after raising its full year 2026 revenue guidance to a range of US$3.4b to US$3.6b, alongside mixed second quarter earnings released on 4 August 2026. See our latest analysis for Knife River. The guidance update and quarterly results have come after a weak stretch for Knife River, with the 30 day share price return down 16.73% and the year to date share price return down 7.18%, even though the three year total shareholder return is 33.57%. If this...
NYSE:BCC
NYSE:BCCTrade Distributors

How Exclusive James Hardie Deal and Capital Returns Will Impact Boise Cascade (BCC) Investors

Boise Cascade Company recently reported past second-quarter 2026 results showing sales of US$1,831.34 million and net income of US$57.34 million, alongside an expanded nationwide distribution agreement under which its Building Materials Distribution division will become the sole U.S. distributor of James Hardie’s full exterior product portfolio from July 31, 2026. The combination of this exclusive James Hardie partnership, a completed share repurchase of 2,377,455 shares for US$178.64...
NYSE:AIN
NYSE:AINMachinery

Why Albany International (AIN) Is Down 18.8% After Strong Q2 2026 Earnings Beat And Upbeat Q3 Outlook

Albany International Corp. reported its second-quarter 2026 results, with sales rising to US$329.48 million and net income to US$17.41 million, alongside higher earnings per share from continuing operations compared with the same period in 2025. Over the first half of 2026, the company delivered year-on-year growth in both revenue and earnings and projected third-quarter consolidated net revenue of US$320 million to US$330 million, signaling management’s confidence in the near-term demand...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story

Harrow, Inc. has reported its past second-quarter 2026 results, with sales rising to US$70.66 million from US$63.74 million a year earlier, while moving from net income of US$5.00 million to a net loss of US$17.27 million. Over the first six months of 2026, sales inched up to US$114.86 million, but the company’s net loss deepened to US$44.87 million, sharply widening its loss per share from continuing operations. We’ll now examine how Harrow’s shift from profit to loss, despite higher sales,...
NasdaqGS:SBRA
NasdaqGS:SBRAHealth Care REITs

How Investors May Respond To Sabra Health Care REIT (SBRA) Profit Reversal And Steady Dividend

In early August 2026, Sabra Health Care REIT, Inc. reported its second-quarter and first-half results, with revenue increasing to US$235.87 million for the quarter and US$457.62 million for the half-year, while moving from net income a year earlier to a net loss of US$25.2 million in the quarter and lower net income of US$15.68 million year to date. Alongside this mixed earnings picture, the company reaffirmed a quarterly dividend of US$0.30 per share payable on August 31, 2026,...
NasdaqGM:HPK
NasdaqGM:HPKOil and Gas

HighPeak Energy (HPK) Beat Expectations, Is The Stock Still Below Fair Value?

Why HighPeak Energy’s latest earnings matter for investors HighPeak Energy (HPK) has drawn fresh attention after reporting second quarter 2026 results on August 10, with revenue of US$272.42 million and net income of US$82.28 million from continuing operations. Management also reported adjusted earnings per share of US$1.06, ahead of prior analyst expectations, along with higher operating and free cash flow margins. These figures sit against a first half backdrop that still includes a...
NasdaqGS:ZM
NasdaqGS:ZMSoftware

Zoom Communications (ZM) Board Exit Puts Its Valuation Back In Focus

Board resignation puts Zoom Communications stock under fresh scrutiny Zoom Communications (ZM) drew new attention after William R. McDermott resigned from the board of directors, effective July 27, 2026, prompting investors to reassess governance and the stock’s recent performance. See our latest analysis for Zoom Communications. The board change comes at a time when Zoom Communications shares have picked up momentum, with a 1 month share price return of 19.43% and a year to date share price...
NYSE:APLE
NYSE:APLEHotel and Resort REITs

Does Apple Hospitality REIT's (APLE) Bigger 2026 Spend and Guidance Shift Its Risk–Reward Balance?

In August 2026, Apple Hospitality REIT, Inc. reported second-quarter revenue of US$402.55 million and net income of US$67.08 million, modestly higher than a year earlier, while also confirming flat first-half earnings per share versus the prior period. Alongside raising its 2026 net income guidance, the company outlined higher planned capital improvements of about US$85 million to US$95 million and expanded, longer-dated credit facilities that leave its US$700 million revolver undrawn. We’ll...
NasdaqGS:RDWR
NasdaqGS:RDWRSoftware

Is Radware (RDWR) Fully Valued Following Q2 Results And Q3 Revenue Guidance?

Q2 results highlight revenue growth and lower profitability Radware (NasdaqGS:RDWR) drew investor focus after reporting second quarter 2026 results on 29 July, with higher sales than a year earlier and lower net income, alongside fresh revenue guidance for the third quarter. The company reported Q2 sales of US$82.28 million, compared with US$74.11 million for the same period in 2025. Net income for the quarter was US$1.71 million, compared with US$4.22 million a year earlier. Basic earnings...